Table 1. FDA-approved GLP-1RAs.

* Excludes GLP-1RA/insulin combination drugs (i.e., Xultophy (liraglutide + insulin degludec) and Soliqua (lixisenatide + insulin glargine)) and drugs with fewer than 100 total cases (i.e., Adlyxin (lixisenatide))

** Dual gastric inhibitory polypeptide receptor and GLP-1RA.

AE, adverse event; BID, twice a day; GLP-1RA, glucagon-like peptide-1 receptor agonist; QD, once a day; QW, once a week

Generic name	Brand name	Indication	FDA approval year	Dosing	Half-life (hours)	Total AEs	Mortality AEs	Serious AEs
Exenatide	Byetta	Type 2 diabetes mellitus	2005	Injection; BID	2	48,898	1,571 (3.2%)	12,423 (25.4%)
Liraglutide	Victoza	Type 2 diabetes mellitus	2010	Injection; QD	13	30,076	1,016 (3.4%)	11,166 (37.1%)
Dulaglutide	Trulicity	Type 2 diabetes mellitus	2014	Injection; QW	120	65,038	942 (1.4%)	12,116 (18.6%)
Liraglutide	Saxenda	Obesity/overweight	2014	Injection; QD	13	5,496	62 (1.1%)	2,221 (40.4%)
Exenatide	Bydureon (BCise)	Type 2 diabetes mellitus	2017	Injection; QW	168-336	29,824	353 (1.2%)	4,890 (16.4%)
Semaglutide	Ozempic	Type 2 diabetes mellitus	2017	Injection; QW	168	20,587	252 (1.2%)	9,031 (43.9%)
Semaglutide	Rybelsus	Type 2 diabetes mellitus	2019	Oral; QD	168	3,310	66 (2.0%)	1,417 (42.8%)
Semaglutide	Wegovy	Obesity/overweight	2021	Injection; QW	168	4,129	34 (0.8%)	1,194 (28.9%)
Tirzepatide**	Mounjaro	Type 2 diabetes mellitus	2022	Injection; QW	120	30,283	110 (0.4%)	2,609 (8.6%)
Tirzepatide**	Zepbound	Obesity/overweight	2023	Injection; QW	120	1,560	0 (0.0%)	49 (3.1%)